EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Uterine artery embolization versus dienogest for symptomatic adenomyosis: A randomized controlled trial of short-term efficacy

Rania Refaat, Eshraq Arabi Mohamed Ammar, Mohammad Abd Alkhalik Basha, Ahmed Mohamed Abouelhoda, Pasant M Abo-Elhoda, Mohamed MohsenTolba Fawzi, Abd El-Aziz Galal El-Dein El-Darwish, Khaled M Abdallah, Ahmed Abdelrady Ahmed

European Journal of Radiology · 2026

DOI: 10.1016/j.ejrad.2026.112712 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Radiology, 2026. Verfasst von Rania Refaat und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic Radiology, Intervention and Molecular Imaging, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Hauptthemen laut MEDLINE: Nandrolone, Adenomyosis, Uterine Artery Embolization. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RATIONALE AND OBJECTIVES: Adenomyosis significantly impairs quality of life, yet optimal uterine-sparing management remains uncertain. While both uterine artery embolization (UAE) and dienogest show promise, no direct comparison exists. This study compared their 6-month efficacy in treating symptomatic adenomyosis. PATIENTS AND METHODS: This prospective, single-center, randomized controlled trial enrolled 60 patients with MRI-confirmed adenomyosis desiring uterine preservation between January and July 2025, randomly assigned (1:1) to UAE (n = 30) or 2 mg/day dienogest (n = 30). Co-primary outcomes were complete resolution of chronic pelvic pain and heavy menstrual bleeding at 6 months. Secondary outcomes included visual analog scale (VAS) dysmenorrhea scores, Uterine Fibroid Symptom and Quality of Life (UFS-QoL) symptom severity and health-related quality of life (HRQOL) scores, hemoglobin levels, junctional zone thickness, and uterine volume measured at baseline, 3 months, and 6 months. RESULTS: UAE achieved higher complete resolution rates for chronic pelvic pain (93.3% vs. 66.7%; p = 0.010; relative risk [RR] = 1.40) and heavy menstrual bleeding (90.0% vs. 56.7%; p = 0.004; RR = 1.59), with composite success in 86.7% versus 50.0% (RR = 1.73; number needed to treat = 3). At 6 months, UAE was associated with significantly better outcomes for VAS dysmenorrhea (1.27 ± 1.23 vs. 2.10 ± 1.25; p = 0.016), symptom severity scores (31.48 ± 9.78 vs. 45.36 ± 9.55; p < 0.001), HRQOL scores (66.25 ± 7.35 vs. 50.82 ± 10.11; p < 0.001), hemoglobin levels (10.55 ± 1.49 vs. 10.19 ± 1.55 g/dL; p = 0.010), junctional zone reduction (33.5% vs. 14.0%; p = 0.005), and uterine volume reduction (17.6% vs. 7.3%; p = 0.006). CONCLUSION: At 6 months, UAE achieved better symptom relief and anatomical outcomes than dienogest, supporting UAE as an effective uterine-sparing therapy for symptomatic adenomyosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NandroloneAdenomyosisUterine Artery EmbolizationHumansFemaleTreatment OutcomeAdultQuality of LifeMiddle AgedProspective StudiesMenorrhagiaMagnetic Resonance Imaging

Stichwörter der Autor:innen

AdenomyosisDienogestMagnetic resonance imagingQuality of lifeUterine artery embolization

Substanzen

Nandrolonedienogest

Autor:innen und Institutionen

  • Department of Diagnostic Radiology, Intervention and Molecular Imaging, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
  • Department of Obstetrics and Gynecology, Faculty of Medicine, Al Azhar University, Assuit, Egypt.
  • Department of Diagnostic Radiology, Faculty of Medicine, Zagazig University, Zagazig, Egypt. Electronic address: Mohammad_basha76@yahoo.com.
  • Department of Radiology, National Hepatology and Tropical Research Institute, Cairo, Egypt.
  • Department of Diagnostic and Interventional Radiology, Faculty of Medicine, Al Azhar University, Assuit, Egypt.

Zitieren

APA

Refaat, R., Ammar, E. A. M., Basha, M. A. A., Abouelhoda, A. M., Abo-Elhoda, P. M., Fawzi, M. M., El-Darwish, A. E. G. E., Abdallah, K. M., & Ahmed, A. A. (2026). Uterine artery embolization versus dienogest for symptomatic adenomyosis: A randomized controlled trial of short-term efficacy. European Journal of Radiology. https://doi.org/10.1016/j.ejrad.2026.112712

Vancouver

Refaat R, Ammar EAM, Basha MAA, Abouelhoda AM, Abo-Elhoda PM, Fawzi MM, et al. Uterine artery embolization versus dienogest for symptomatic adenomyosis: A randomized controlled trial of short-term efficacy. European Journal of Radiology. 2026. doi:10.1016/j.ejrad.2026.112712

BibTeX
@article{Refaat2026,
  author = {Refaat, Rania and Ammar, Eshraq Arabi Mohamed and Basha, Mohammad Abd Alkhalik and Abouelhoda, Ahmed Mohamed and Abo-Elhoda, Pasant M and Fawzi, Mohamed MohsenTolba and El-Darwish, Abd El-Aziz Galal El-Dein and Abdallah, Khaled M and Ahmed, Ahmed Abdelrady},
  title = {Uterine artery embolization versus dienogest for symptomatic adenomyosis: A randomized controlled trial of short-term efficacy},
  journal = {European Journal of Radiology},
  year = {2026},
  doi = {10.1016/j.ejrad.2026.112712}
}
Kostenlos starten →